Anti-Neoplastic Agents Global Market Report 2024

The global anti-neoplastic agents market has grown rapidly in recent years. It will grow from $118.03 billion in 2023 to $130.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.

The global anti-neoplastic agents market is expected to see strong growth in the next few years. It will grow to $184.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.

The growing incidence of cancer is projected to drive the expansion of the antineoplastic agent market in the future. Cancer encompasses a spectrum of diseases that can originate in almost any organ or tissue within the body, characterized by the uncontrolled proliferation of abnormal cells that breach their natural boundaries, potentially spreading to other organs or invading neighboring tissues. Antineoplastic agents assume a crucial role in cancer treatment by inhibiting the growth and division of cancerous cells through diverse mechanisms, including DNA damage, disruption of the cell cycle, and interference with vital cellular pathways. For example, in 2023, as reported by the American Cancer Society Inc., a nonprofit health organization based in the United States, it is estimated that there will be approximately 1.9 million new cancer cases diagnosed in the US, marking an increase from the 1.8 million cases identified in 2020. Moreover, it is anticipated that there will be 609,820 cancer-related deaths in 2023, compared to 606,520 in 2020. Consequently, the rising incidence of cancer is a significant driver of growth in the antineoplastic agent market.

The growth of the anti-neoplastic agent market is expected to be driven by an increase in investment in cancer research. This investment involves allocating financial resources to support scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. The additional funding for cancer research enables pharmaceutical and biotechnology companies to explore, develop, and rigorously test new anti-neoplastic agents, which includes identifying potential drug targets and creating candidate compounds. For example, in March 2022, the Australian Department of Health and Aged Care allocated $893.5 million to improve cancer services and outcomes. A portion of this investment, $329.4 million, is earmarked for new cancer drugs like Trodelvy, Lynparza, and Mylotarg, which can potentially benefit hundreds of patients annually. Consequently, the increased investment in cancer research is poised to drive the growth of the anti-neoplastic agent market.

The anti-neoplastic agents market could face significant hindrances in its growth due to the substantial expenses associated with these drugs. Developing neoplastic agents is a costly process, and the varied nature of cancer further contributes to these high costs. As an illustration, in May 2023, data from IQVIA Inc., a US-based company specializing in healthcare information technology and pharmaceutical clinical research, indicated that there has been an increase in the number of new cancer drugs with annual expenses exceeding $200,000. In the previous year, the expenditure on high-cost cancer therapies reached $48 billion, with the median yearly price for new oncology medications standing at $260,000. Hence, the exorbitant expenses of anti-neoplastic agents impede the growth of this market.

Leading companies in the field of anti-neoplastic agents are dedicated to the development of clinical practices to maintain their market position. For instance, in March 2022, Novartis AG, a pharmaceutical company headquartered in Switzerland, announced the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto is the first targeted radioligand therapy approved for the treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) that is positive for PSMA (Prostate-specific membrane antigen). The recommended treatment regimen involves administering 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses, with treatment cessation upon disease progression or if intolerable toxicity occurs, whichever happens first. Patient selection for Pluvicto treatment in previously treated mCRPC should be based on the assessment of PSMA expression in tumors, employing Locametz or another authorized PSMA-11 imaging agent.

In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, completed the acquisition of Epizyme Inc. for a total of $247 million. This strategic move by Ipsen is intended to broaden its oncology portfolio by incorporating Tazverik, an innovative EZH2 inhibitor that offers a chemotherapy-free treatment option. Epizyme Inc., based in the United States, is a biopharmaceutical company known for its contributions in the field of anti-neoplastic agents.

Major players in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the anti-neoplastic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-neoplastic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of anti-neoplastic agents are alkylating agents, antimetabolites, hormones and antagonists and miscellaneous. Alkylating agents are a class of chemical compounds that can add alkyl groups to DNA, RNA and proteins, disrupting their normal function and interfering with cell replication. These are used to treat several diseases, including gastrointestinal cancer, prostate cancer, lung cancer, breast cancer and others and are used by various end users, such as hospitals, clinics, cancer rehabilitation centers and ambulatory surgical centers.

This report provides anti-neoplastic agents market statistics, including anti-neoplastic agent industry global market size, regional shares, competitors with an anti-neoplastic agent market share, detailed anti-neoplastic agents market segments, market trends and opportunities and any further data you may need to thrive in the anti-neoplastic agent industry. This anti-neoplastic agent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-neoplastic agents market consists of sales of antitumor antibiotics, microtubule inhibitors and topoisomerase inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.